Echt M L, Finan M A, Hoffman M S, Kline R C, Roberts W S, Fiorica J V
Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa, USA.
South Med J. 1999 Feb;92(2):204-8. doi: 10.1097/00007611-199902000-00008.
Identification of sentinel lymph nodes may allow prediction of metastatic disease in cancer patients. We did a prospective study to determine whether lymphazurin dye could identify sentinel lymph nodes in patients with cervical, uterine, and vulvar cancer.
In 33 patients having surgery for either uterine, cervical, or vulvar carcinoma, lymphazurin dye was injected into the respective organs before the tumor and node dissection began. Sentinel lymph nodes were identified and dissected in situ.
The identification rate of sentinel lymph nodes was 0/8 (0%) for uterine cancer patients, 2/13 (15.4%) for cervical cancer patients, and 9/12 for vulvar cancer patients (75%).
In a limited number of patients, lymphazurin day may be useful in identifying or assessing the sentinel nodes draining vulvar and cervical cancers. The role of this procedure in treatment planning for patients with gynecologic malignancies is yet to be determined.
前哨淋巴结的识别有助于预测癌症患者的转移性疾病。我们进行了一项前瞻性研究，以确定亚甲蓝染料是否能识别宫颈癌、子宫癌和外阴癌患者的前哨淋巴结。
在33例接受子宫、宫颈或外阴癌手术的患者中，在肿瘤和淋巴结切除开始前，将亚甲蓝染料注入相应器官。原位识别并切除前哨淋巴结。
子宫癌患者前哨淋巴结识别率为0/8（0%），宫颈癌患者为2/13（15.4%），外阴癌患者为9/12（75%）。
在有限数量的患者中，亚甲蓝可能有助于识别或评估引流外阴癌和宫颈癌的前哨淋巴结。该方法在妇科恶性肿瘤患者治疗规划中的作用尚待确定。
